# Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

> **NCT00186498** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 11 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** memantine
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT00186498
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2006-02
- **Final completion:** 2008-02
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00186498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00186498, "Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00186498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*